Audit of cabozantinib outcomes for metastatic renal cell carcinoma at Norfolk and Norwich University Hospital

e16538 Background: Kidney cancer remains the seventh most common solid organ cancer in the UK, USA and Europe, with renal cell carcinoma forming most of these cases [1]. In the UK, kidney cancer accounts for 3% of all new cancer diagnoses of which 25–31% present with metastatic RCC (mRCC) at initial diagnosis. [2] Methods: The METEOR trial was used as the comparator for response rates and progression-free survival to evaluate our outcomes. In the METEOR trial, treatment with Cabozantinib was associated with significantly better overall survival (OS) (21.4 months (m) with Cabozantinib vs 16.5m Everolimus), progression-free survival (PFS) (7.4m vs 3.9m), objective response rates (ORR) (17% vs 3%), and an equivalent safety profile when compared to Everolimus, a second-line treatment for patients with advanced renal cell carcinoma. [3] We present the results of Cabozantinib outcomes in the first to third line setting for mRCC at an NHS tertiary hospital. A direct comparison of OS is not feasible, as the METEOR data was for Cabozantinib in the second line. In contrast, Cabozantinib was used in first, second and subsequent line settings according to the NHS funding in our hospital trust. Results: From 16 April 2018 to 13 November 2023, 43 patients with mRCC received Cabozantinib at our NHS trust. Compared to the METEOR study, the median follow-up for our NHS tertiary centre patients was 7.5 m, as opposed to 18.7 m. Comparing the real-world data from our NHS centre with the METEOR trial, the ORR (partial response according to RECIST criteria) was 25% compared to 17%, whilst the PFS was 10.6m vs 7.4m. Interestingly, we observed that patients who had received immunotherapy before Cabozantinib had significantly better PFS (12m OS = 22% vs 0%; Log Rank = 0.03). Grade 3 and above toxicities was 32.5% vs 71% (NHS hospital vs METEOR trial). Conclusions: Overall, Cabozantinib showed better than expected response rates, and the toxicities in our NHS tertiary hospital were less severe than in the METEOR trial. Significantly, we observed that individuals who had received immunotherapy before Cabozantinib had higher survival outcomes. References: 1. U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2022 submission data (1999-2020): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https://www.cdc.gov/cancer/dataviz , released in November 2023; 2. Cancer Research UK [Internet]. Kidney cancer statistics. Available from: http://www.cancerresearchuk.org/healthprofessional/cancer-statistics/statistics-by-cancer-type/kidney-cancer. [Cited: 2019 Jan 15]; 3. Choueiri, Toni K., et al. "Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial." The Lancet Oncology 17.7 (2016): 917-927.

Cabozantinib outcomes for metastatic renal cell carcinoma at a tertiary NHS hospital in the United Kingdom (UK).

871 Impact of Hydrogel Spacer on Quality of Life and Dosimetry in Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

David Maskell

Author Tools

Chat about Author

Papers

Audit of cabozantinib outcomes for metastatic renal cell carcinoma at Norfolk and Norwich University Hospital

Cabozantinib outcomes for metastatic renal cell carcinoma at a tertiary NHS hospital in the United Kingdom (UK).

871 Impact of Hydrogel Spacer on Quality of Life and Dosimetry in Hypofractionated External Beam Radiotherapy for Localized Prostate Cancer